文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

大麻药物临床试验:澳大利亚经验对伦理审查与治理的指导

Clinical trials with cannabis medicines-guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience.
PubMed 文献 · Trials · 2020-11-17

随着大麻药物在多国获得合法地位,消费者需求快速增长,但缺乏最佳使用知识及监管标准下的临床试验证据。本文基于澳大利亚研究人员经验,描述了大麻药物临床试验在伦理审查与治理中常见的困难,如研究产品安全性数据不足、药物相互作用、供应连续性、保质期和储存等问题,并提供了实用建议以帮助研究人员、伦理委员会和治理官员应对这些挑战。

要点

  • 大麻药物临床试验常在产品安全性数据不足时启动,引发伦理委员会担忧。
  • 伦理与治理审查延迟是大麻药物试验启动的主要障碍之一。
  • 本文提供实用建议以简化伦理申请并确保患者安全。

核心结论

  • 大麻药物临床试验在伦理和治理审查阶段面临独特挑战,常导致审批延迟。
  • 缺乏产品安全性、药物相互作用、供应连续性、保质期和储存数据是伦理委员会担忧的核心。
  • 本文提出的建议基于澳大利亚经验,但可适应其他司法管辖区。

研究设计与样本

  • 本文基于澳大利亚参与大麻药物临床试验的研究人员和工作人员的经验。
  • 描述了伦理审查与治理过程中常见的困难,并提供实用建议。

主要发现

  • 大麻药物临床试验常在产品临床前和药学安全性问题未确立前使用研究产品。
  • 产品安全性数据缺乏、潜在药物相互作用、供应连续性、保质期和储存问题导致伦理委员会和治理机构对批准试验持谨慎态度。
  • 伦理与治理审查的延迟常导致试验启动时间延长。

临床怎么用

  • 研究人员可参考本文建议准备伦理申请,以简化审批流程。
  • 伦理委员会和治理官员可参考本文建议导航大麻药物临床试验的复杂领域。

局限性

  • 作者经验基于澳大利亚环境,但许多障碍在国际背景下适用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With cannabis medicines now obtaining legal status in many international jurisdictions (generally on the authorisation of a medical professional), a rapid increase in consumer demand for access to cannabis as a therapeutic option in the treatment and management of a range of indications is being noted. Despite this accessibility, knowledge on optimal use is lacking. Further drug development and clinical trials at regulatory standards are necessary both if a better understanding of the efficacy of cannabis medicines, optimal product formulation and indication-specific dosing is needed and to ensure the broader quality and safety of cannabis medicines in the clinical setting.To enable this, clinical, academic and public calls for the undertaking of rigorous clinical trials to establish an evidence base for the therapeutic use of cannabis medicines have been made internationally. While this commitment to undertake human studies with cannabis medicines is welcomed, it has highlighted unique challenges, notably in the review stages of ethics and governance. This often results in lengthy delays to approval by Human Research Ethics Committees (herein 'HREC', Australia's nomenclature for Institutional Review Boards) and trial commencement. A principal concern in these cases is that in contrast to clinical trials using other more conventional pharmaceutical products, trials of cannabis medicines in humans often involve the use of an investigational product prior to some (or any) of the preclinical and pharmaceutical safety issues being established. This paucity of data around product safety, potential drug interactions, continuity of supply, shelf life and product storage results in apprehension by HRECs and governance bodies to endorse trials using cannabis medicines.This manuscript draws from the experiences of Australian researchers and staff involved in clinical trials of cannabis medicines to describe some of the common difficulties that may be faced in the HREC approval process. It also presents practical advice aimed to assist researchers, HRECs and governance officers navigate this complex terrain. While the authors' experiences are situated within the Australian setting, many of the barriers described are applicable within the international context and thus, the solutions that have been proposed are typically adaptive for use within other jurisdictions.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Martin JH, Hill C, Walsh A, et al. Clinical trials with cannabis medicines-guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience. Trials. 2020. PMID: 33203469. doi:10.1186/s13063-020-04862-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。